Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities

Chest

Volumn 135, Issue 1, 2009, Pages 122-129

  McGoon, Michael D ^a   Frost, Adaani E ^b   Oudiz, Ronald J ^c   Badesch, David B ^d   Galie, Nazzareno ^e   Olschewski, Horst ^f   McLaughlin, Vallerie V ^g   Gerber, Michael J ^h   Dufton, Chris ^h   Despain, Darrin J ^h   Rubin, Lewis J ⁱ  

^a MAYO CLINIC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g UNIVERSITY OF MICHIGAN   (United States)

^h Gilead Sciences   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ambrisentan; Bosentan; Endothelin receptor antagonist; Hepatotoxicity; Liver function test; Propanoic acid; Pulmonary hypertension; Serum aminotransferase; Sitaxsentan; Sulfonamide

Indexed keywords

AMBRISENTAN; BOSENTAN; DIURETIC AGENT; PROSTANOID; SILDENAFIL; SITAXSENTAN;

ADOLESCENT; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHILD; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FEMALE; FLUSHING; HEADACHE; HEART PALPITATION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIVER FUNCTION TEST; MALE; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCHOOL CHILD; SHORT FORM 36; SIDE EFFECT;

EID: 58249107821     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-1028     Document Type: Article

References (20)

1. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352:719-725
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 199; 115:343-349
3. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:1119-1123
4. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903
5. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25:244-249
6. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-a receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47:2049-2056
7. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169:441-447
8. Channick RN, Sitbon O, Barst RJ, et al. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(12 suppl S):62S-67S
9. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46:529-535
10. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354:731-739
11. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001; 69:223-231
12. Fouassier L, Kinnman N, Lefevre G, et al. Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J Hepatol 2002; 37:184-191
13. Brouwer KR, Wille KR, Gorczynski RJ. Ambrisentan, darusentan, bosentan, and sitaxsentan: differences in inhibition of hepatobilliary transporters in two species [abstract]. Drug Metab Rev 2007; 39(suppl):1-388
14. Olschewski H, Galie N, Ghofrani HA, et al. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension. Results of the ARIES-2 Study. Proc Am Thorac Soc 2006; 3:A728
15. Oudiz R, Torres F, Frost AE, et al. ARIES-1: A placebo-controlled, efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension. Chest 2006; 130:121S
16. Abbott SD, Fagan-Smith EA, Coyne TC. Background incidence of elevated liver aminotransferases in pulmonary arterial hypertension (PAH): results from 4 placebo-controlled trials. Proc Am Thorac Soc 2006; 3:A512
17. Luscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002; 106:2666-2672
18. Nakov R, Pfarr E, Eberle S. Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 2002; 15(7 pt 1):583-589
19. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110:1959-1966
20. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21:679-689